Dr. D. Lansing Taylor is the Director at the University of Pittsburgh Drug Discovery Institute and an expert on Computational Biology. He has translated that expertise into more than 29 patents and multiple successful startups
His companies include Biological Detection Systems (now owned by GE Life Sciences), Cellomics (acquired by ThermoFisher), and Cellumen (now part of Cyprotex). Dr. Taylor’s current companies are Spintellx and BioSystics. Spintellx focuses on computational pathology, using machine learning to identify abnormalities in tissue samples. BioSystics is a database and analytics firm that creates digital twins from complex data for research institutions and Big Pharma clients. In this episode, Dr. Taylor and Aaron discuss the potential of precision medicine, the application of digital twins, and how doctors will work with data in the future. Dr. D Lansing Taylor’s Challenge; Continue encouraging your government officials to support basic medical research. Connect with Dr. D. Lansing Taylor
Linkedin
Website If you liked this interview, check out Building a Billion Dollar Company Treating Rare Diseases w/ Dr Gordon Vanscoy
2 Comments
7/14/2022 01:37:46 am
I admire your work here about medicine on your blog that would be useful. There are the people who might looking for the help about that would works to all. I was looking for the help about health care information please do share more. 8/11/2022 02:21:24 am
If you haven't heard of 536 Precision Medicine Startups, you probably don't know what precision medicine is. What started out as a research topic in the 1980 s has become a booming industry which is still growing at an incredible rate. Leave a Reply. |
Show NotesFind links and information referenced in each episode. 
Archives
September 2022
|
RSS Feed